IvyRock Asset Management HK Ltd Makes New Investment in Arrowhead Pharmaceuticals, Inc. $ARWR

IvyRock Asset Management HK Ltd acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 10,500 shares of the biotechnology company’s stock, valued at approximately $362,000. Arrowhead Pharmaceuticals makes up about 0.2% of IvyRock Asset Management HK Ltd’s portfolio, making the stock its 12th largest holding.

Several other large investors also recently modified their holdings of ARWR. Marex Group plc bought a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at $576,000. Nordea Investment Management AB boosted its stake in Arrowhead Pharmaceuticals by 74.5% in the third quarter. Nordea Investment Management AB now owns 372,282 shares of the biotechnology company’s stock valued at $12,661,000 after buying an additional 158,937 shares in the last quarter. Marshall Wace LLP boosted its stake in Arrowhead Pharmaceuticals by 3,507.8% in the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after buying an additional 2,096,238 shares in the last quarter. HBK Sorce Advisory LLC bought a new position in Arrowhead Pharmaceuticals in the third quarter valued at about $2,823,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in Arrowhead Pharmaceuticals during the third quarter worth about $287,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Trading Down 3.2%

Shares of NASDAQ ARWR opened at $61.62 on Thursday. The firm has a 50 day moving average price of $66.28 and a two-hundred day moving average price of $47.91. The stock has a market cap of $8.63 billion, a P/E ratio of 40.27 and a beta of 1.21. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $9.57 and a 52-week high of $76.76. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The business had revenue of $264.03 million for the quarter, compared to analyst estimates of $225.66 million. During the same quarter last year, the firm posted ($1.39) EPS. Arrowhead Pharmaceuticals’s revenue for the quarter was up 10461.3% on a year-over-year basis. As a group, equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 130,000 shares of the company’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $68.85, for a total value of $8,950,500.00. Following the sale, the chief executive officer owned 3,971,255 shares in the company, valued at approximately $273,420,906.75. The trade was a 3.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider James C. Hamilton sold 40,164 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $2,534,750.04. Following the completion of the sale, the insider directly owned 171,958 shares of the company’s stock, valued at approximately $10,852,269.38. The trade was a 18.93% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 510,836 shares of company stock valued at $33,603,060 over the last 90 days. 3.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ARWR. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 10th. B. Riley Financial raised their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Royal Bank Of Canada boosted their target price on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research note on Thursday, December 11th. The Goldman Sachs Group increased their price target on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, January 7th. Finally, Piper Sandler reissued an “overweight” rating and set a $110.00 price objective (up from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $81.67.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.